202(top 1%)
PR articles
27.9K(top 1%)
PR citations
59(top 1%)
PR h-index
69(top 1%)
h-index
246
documents
36.4K
doc citations
2.4K
citing journals
100
times ranked

Publications

210 PR articles • 29,545 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1High-Grade Follicular Cell-Derived Non-Anaplastic Thyroid Carcinoma: Correlating Extent of Invasion and Mutation Profile with Oncologic Outcome
Thyroid, 2025, 35, 153-165
4.48Citations (PDF)
2A Clinical Nomogram to Predict Survival Outcomes in Patients with Well-Differentiated Thyroid Cancer
Thyroid, 2025, 35, 397-405
4.42Citations (PDF)
3Partial Thyroidectomy With Incidental Metastatic Lymph Nodes3.09Citations (PDF)
4Response to Letter to the Editor From Jagannath and Mayilvaganan: “Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?”4.10Citations (PDF)
5Redefining Actionable Disease in Well-differentiated Thyroid Cancer Management4.10Citations (PDF)
6Outcomes of Conversion Surgery for Patients With Low-Risk Papillary Thyroid Carcinoma3.08Citations (PDF)
7Defining the Genomic Landscape of Diffuse Sclerosing Papillary Thyroid Carcinoma: Prognostic Implications of RET Fusions
Annals of Surgical Oncology, 2024, 31, 5525-5536
2.36Citations (PDF)
8Role of Locoregional Therapies in the Treatment of Thyroid Pathology: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel1.11Citations (PDF)
9Diffuse Sclerosing Papillary Thyroid Carcinoma: Clinicopathological Characteristics and Prognostic Implications Compared with Classic and Tall Cell Papillary Thyroid Cancer
Annals of Surgical Oncology, 2023, 30, 4761-4770
2.37Citations (PDF)
10Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?4.17Citations (PDF)
11Is There a Role for Levothyroxine Therapy in Euthyroid Patients on Active Surveillance for Papillary Microcarcinoma?
Thyroid, 2023, 33, 1137-1139
4.42Citations (PDF)
12Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma?
Surgery, 2022, 171, 1341-1347
1.811Citations (PDF)
13Invasion of a Recurrent Laryngeal Nerve from Small Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance
Thyroid, 2022, 32, 164-169
4.426Citations (PDF)
14Enhancing Radioiodine Incorporation in BRAF -Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Thyroid, 2022, 32, 273-282
4.447Citations (PDF)
15Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes
Thyroid, 2022, 32, 245-254
4.437Citations (PDF)
16Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy
Thyroid, 2022, 32, 28-36
4.435Citations (PDF)
17Letter to the Editor From Boucai and Tuttle: “BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-Associated Mortality Risk in Papillary Thyroid Cancer”4.11Citations (PDF)
18American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
Head and Neck, 2022, 44, 1277-1300
2.0100Citations (PDF)
19The solid variant of papillary thyroid carcinoma: a multi‐institutional retrospective study
Histopathology, 2022, 81, 171-182
3.617Citations (PDF)
20A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer
Thyroid, 2022, 32, 799-806
4.427Citations (PDF)
21Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy1.97Citations (PDF)
22Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting
Human Pathology, 2021, 110, 62-72
2.331Citations (PDF)
23How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?
Endocrine Practice, 2021, 27, 607-613
3.311Citations (PDF)
24Frequent neck US in papillary thyroid cancer likely detects non‐actionable findings
Clinical Endocrinology, 2021, 94, 504-512
2.39Citations (PDF)
25Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival
Annals of Surgical Oncology, 2021, 28, 6572-6579
2.346Citations (PDF)
26Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer
Endocrine Practice, 2021, 27, 383-389
3.313Citations (PDF)
27Abnormal growth rate of a benign cervical sympathetic chain schwannoma
Otolaryngology Case Reports, 2021, 19, 100295
0.23Citations (PDF)
28Ultrasound-Guided Percutaneous Laser Ablation of the Thyroid Gland in a Swine Model: Comparison of Ablation Parameters and Ablation Zone Dimensions.1.77Citations (PDF)
29A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer
Thyroid, 2021, 31, 1009-1019
4.484Citations (PDF)
30Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial
Cancer, 2021, 127, 4161-4170
4.024Citations (PDF)
31Nuances in the Surgical Management of Thyroid Cancer0.51Citations (PDF)
32Papillary microcarcinoma—Management issues0.91Citations (PDF)
33Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?
Surgery, 2020, 167, 10-17
1.865Citations (PDF)
34Dynamic contrast‐enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers
NMR in Biomedicine, 2020, 33,
2.423Citations (PDF)
35Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center4.1137Citations (PDF)
36Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma
Thyroid, 2020, 30, 688-695
4.425Citations (PDF)
37ThyroidEx: Development and Preliminary Validation of a Thyroid Surgery Expectations Measure2.34Citations (PDF)
38Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the US3.011Citations (PDF)
39Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies
Thyroid, 2020, 30, 1112-1119
4.427Citations (PDF)
40Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer
Journal of Nuclear Medicine, 2020, 61, 375-396
5.530Citations (PDF)
41Active surveillance for patients with very low‐risk thyroid cancer1.638Citations (PDF)
42Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome
Modern Pathology, 2020, 33, 1690-1701
4.860Citations (PDF)
43Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases
Thyroid, 2020, 30, 1505-1517
4.4252Citations (PDF)
44Is a Prophylactic Central Compartment Neck Dissection Required in Papillary Thyroid Carcinoma Patients with Clinically Involved Lateral Compartment Lymph Nodes?
Annals of Surgical Oncology, 2020, 28, 512-518
2.322Citations (PDF)
45Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country
Endocrine, 2020, 72, 721-726
2.54Citations (PDF)
46How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
Thyroid, 2019, 29, 1792-1803
4.450Citations (PDF)
47Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases4.138Citations (PDF)
48Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma
Annals of Surgical Oncology, 2019, 26, 4423-4429
2.312Citations (PDF)
49Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features
Endocrine, 2019, 64, 97-108
2.552Citations (PDF)
50Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer3.516Citations (PDF)
51Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up4.1145Citations (PDF)
52Commentary “Incidence of total thyroidectomy and lobectomy”
Surgery, 2019, 166, 48-49
1.80Citations (PDF)
53Enhanced interdisciplinary communication: development of an interactive thyroid nodule/cancer disease map
Laryngoscope, 2019, 129, 269-274
1.41Citations (PDF)
54American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence‐based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules
Head and Neck, 2019, 41, 843-856
2.012Citations (PDF)
55European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium
Thyroid, 2019, 29, 7-26
4.4154Citations (PDF)
56Vemurafenib Redifferentiation of <i>BRAF</i> Mutant, RAI-Refractory Thyroid Cancers4.1217Citations (PDF)
57Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer
Surgery, 2019, 165, 6-11
1.854Citations (PDF)
58Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement
Head and Neck, 2018, 40, 663-675
2.079Citations (PDF)
59A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management2.973Citations (PDF)
60Controversial Issues in Thyroid Cancer Management
Journal of Nuclear Medicine, 2018, 59, 1187-1194
5.587Citations (PDF)
61Treatment decision making in early‐stage papillary thyroid cancer
Psycho-Oncology, 2018, 27, 61-68
3.049Citations (PDF)
62Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual251.8323Citations (PDF)
63Risk Stratification in Differentiated Thyroid Cancer: Importance and Clinical Implications of Preoperative Risk Stratification0.11Citations (PDF)
64Implementing Key Changes in The American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types
Endocrine Practice, 2018, 24, 833-840
3.312Citations (PDF)
65Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease
Thyroid, 2018, 28, 1180-1189
4.432Citations (PDF)
66Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer
Thyroid, 2018, 28, 1293-1300
4.449Citations (PDF)
67Thyroid Cancer Treatment Choice: A Pilot Study of a Tool to Facilitate Conversations with Patients with Papillary Microcarcinomas Considering Treatment Options
Thyroid, 2018, 28, 1325-1331
4.453Citations (PDF)
68Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
Thyroid, 2017, 27, 512-517
4.4121Citations (PDF)
69Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer5.151Citations (PDF)
70The “broken chair” in patients with differentiated thyroid cancer
Endocrine, 2017, 57, 359-360
2.51Citations (PDF)
71Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer
Clinical Endocrinology, 2017, 87, 566-571
2.320Citations (PDF)
72Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Clinical Cancer Research, 2017, 23, 5970-5980
6.8111Citations (PDF)
73Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low‐risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary1.88Citations (PDF)
74Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?4.10Citations (PDF)
75Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell‐derived thyroid carcinoma
Cancer, 2017, 123, 2955-2964
4.082Citations (PDF)
76Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics
Thyroid, 2017, 27, 632-640
4.460Citations (PDF)
77Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance3.0433Citations (PDF)
78Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer
Thyroid, 2017, 27, 396-401
4.438Citations (PDF)
79Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry–Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer
Journal of Nuclear Medicine, 2017, 58, 717-722
5.597Citations (PDF)
80The History of the Follicular Variant of Papillary Thyroid Carcinoma4.1120Citations (PDF)
81Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?
Endocrine, 2017, 59, 143-150
2.565Citations (PDF)
82Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine2.52Citations (PDF)
83Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer0.711Citations (PDF)
84External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society
Head and Neck, 2016, 38, 493-498
2.096Citations (PDF)
85Active Surveillance for Papillary Thyroid Microcarcinoma: New Challenges and Opportunities for The Health Care System
Endocrine Practice, 2016, 22, 602-611
3.371Citations (PDF)
86Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
JAMA Oncology, 2016, 2, 1023
14.41,332Citations (PDF)
87Changing Trends in the Incidence of Thyroid Cancer in the United States3.0178Citations (PDF)
88Challenges of Active Surveillance Protocols for Low-Risk Papillary Thyroid Microcarcinoma in the United States
Thyroid, 2016, 26, 989-990
4.416Citations (PDF)
89Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine4.1213Citations (PDF)
90Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?21.8226Citations (PDF)
91Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell–Derived Thyroid Carcinomas
Thyroid, 2016, 26, 1588-1597
4.465Citations (PDF)
92Multi‐institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion‐weighted MRI
Magnetic Resonance in Medicine, 2016, 75, 1708-1716
2.856Citations (PDF)
93Operative management of locally advanced, differentiated thyroid cancer
Surgery, 2016, 160, 738-746
1.882Citations (PDF)
94Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6–NTRK3 fusion
Modern Pathology, 2016, 29, 985-995
4.883Citations (PDF)
95Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell–Derived Thyroid Cancer
Thyroid, 2016, 26, 518-524
4.451Citations (PDF)
96An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer
Thyroid, 2016, 26, 373-380
4.4199Citations (PDF)
97Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes
Thyroid, 2016, 26, 219-226
4.464Citations (PDF)
98Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid
Surgery, 2016, 159, 1390-1395
1.816Citations (PDF)
99A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma
Thyroid, 2016, 26, 144-149
4.4301Citations (PDF)
100Management of advanced medullary thyroid cancer21.8116Citations (PDF)
1012015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid, 2016, 26, 1-133
4.413,083Citations (PDF)
102Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation2.126Citations (PDF)
103Serial Neck Ultrasound is More Likely to Identify False-Positive Abnormalities than Clinically Significant Disease in Low-Risk Papillary Thyroid Cancer Patients
Endocrine Practice, 2015, 21, 1372-1379
3.350Citations (PDF)
104Cost‐effectiveness analysis of papillary thyroid cancer surveillance
Cancer, 2015, 121, 4132-4140
4.056Citations (PDF)
105RAI thyroid bed uptake after total thyroidectomy: A novel SPECT‐CT anatomic classification system
Laryngoscope, 2015, 125, 2417-2424
1.428Citations (PDF)
106Practical Barriers to Implementation of Thyroid Cancer Guidelines in the Asia-Pacific Region
Endocrine Practice, 2015, 21, 1255-1268
3.312Citations (PDF)
107Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare
Thyroid, 2015, 25, 865-866
4.47Citations (PDF)
108Management of Recurrent/Persistent Nodal Disease in Patients with Differentiated Thyroid Cancer: A Critical Review of the Risks and Benefits of Surgical Intervention Versus Active Surveillance
Thyroid, 2015, 25, 15-27
4.4130Citations (PDF)
109Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence
Thyroid, 2015, 25, 1235-1242
4.442Citations (PDF)
110Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates
Cancer, 2015, 121, 1793-1799
4.079Citations (PDF)
111Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant
Human Pathology, 2015, 46, 657-664
2.3131Citations (PDF)
112Using Diffusion-Weighted MRI to Predict Aggressive Histological Features in Papillary Thyroid Carcinoma: A Novel Tool for Pre-Operative Risk Stratification in Thyroid Cancer
Thyroid, 2015, 25, 672-680
4.436Citations (PDF)
113Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer
Annals of Surgical Oncology, 2015, 22, 3530-3536
2.346Citations (PDF)
114Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma
Thyroid, 2015, 25, 503-508
4.458Citations (PDF)
115Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study
Journal of Nuclear Medicine, 2015, 56, 662-667
5.543Citations (PDF)
116Frequent Screening With Serial Neck Ultrasound Is More Likely to Identify False-Positive Abnormalities Than Clinically Significant Disease in the Surveillance of Intermediate Risk Papillary Thyroid Cancer Patients Without Suspicious Findings on Follow-Up Ultrasound Evaluation4.144Citations (PDF)
117Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure
Thyroid, 2015, 25, 993-998
4.452Citations (PDF)
118Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?
Thyroid, 2015, 25, 1106-1114
4.4169Citations (PDF)
119Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell–derived thyroid carcinomas: a clinicopathologic study of 276 cases
Human Pathology, 2015, 46, 1789-1798
2.382Citations (PDF)
120Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma
Thyroid, 2015, 25, 300-307
4.4146Citations (PDF)
121Response to Initial Therapy Predicts Clinical Outcomes in Medullary Thyroid Cancer
Thyroid, 2015, 25, 242-249
4.491Citations (PDF)
122Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer
Annals of Surgical Oncology, 2015, 23, 410-415
2.398Citations (PDF)
123Restricting ultrasound thyroid fine needle aspiration biopsy by nodule size: which tumors are we missing? A population-based study
Endocrine, 2015, 51, 499-505
2.57Citations (PDF)
124Preoperative Neck Ultrasound in Clinical Node-Negative Differentiated Thyroid Cancer4.116Citations (PDF)
125Central Lymph Node Characteristics Predictive of Outcome in Patients with Differentiated Thyroid Cancer
Thyroid, 2014, 24, 1790-1795
4.444Citations (PDF)
126Multi-Organ Distant Metastases Confer Worse Disease-Specific Survival in Differentiated Thyroid Cancer
Thyroid, 2014, 24, 1594-1599
4.493Citations (PDF)
127The 2009 American Thyroid Association Guidelines Modestly Reduced Radioactive Iodine Use for Thyroid Cancers Less Than 1 cm
Thyroid, 2014, 24, 1549-1550
4.412Citations (PDF)
128Prognostic Factors in Papillary Microcarcinoma with Emphasis on Histologic Subtyping: A Clinicopathologic Study of 148 Cases
Thyroid, 2014, 24, 245-253
4.462Citations (PDF)
129Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system?
Surgery, 2014, 156, 1484-1490
1.826Citations (PDF)
130What Is the Gold Standard for Comprehensive Interinstitutional Communication of Perioperative Information for Thyroid Cancer Patients? A Comparison of Existing Electronic Health Records with the Current American Thyroid Association Recommendations
Thyroid, 2014, 24, 1466-1472
4.416Citations (PDF)
131Higher Administered Activities of Radioactive Iodine Are Associated with Less Structural Persistent Response in Older, but Not Younger, Papillary Thyroid Cancer Patients with Lateral Neck Lymph Node Metastases
Thyroid, 2014, 24, 1088-1095
4.450Citations (PDF)
132The impact of nodal status on outcome in older patients with papillary thyroid cancer
Surgery, 2014, 156, 137-146
1.8102Citations (PDF)
133Update on Differentiated Thyroid Cancer Staging3.5178Citations (PDF)
134Thyroid Carcinoma, Version 2.201412.6156Citations (PDF)
135Level 7 Disease Does Not Confer Worse Outcome than Level 6 Disease in Differentiated Thyroid Cancer
Annals of Surgical Oncology, 2014, 22, 441-445
2.31Citations (PDF)
136Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer16.6859Citations (PDF)
137Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems
Thyroid, 2013, 23, 1401-1407
4.4144Citations (PDF)
138American Thyroid Association Statement on Outpatient Thyroidectomy
Thyroid, 2013, 23, 1193-1202
4.4262Citations (PDF)
139Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging
Oral Oncology, 2013, 49, 695-701
2.449Citations (PDF)
140Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence
Annals of Surgical Oncology, 2013, 20, 2285-2289
2.362Citations (PDF)
141Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: A practical approach to clinical decision making
Oral Oncology, 2013, 49, 676-683
2.440Citations (PDF)
142A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer Patients
Thyroid, 2013, 23, 436-442
4.460Citations (PDF)
143Recombinant Human Thyroid-Stimulating Hormone To Stimulate 131-1 Uptake For Remnant Ablation And Adjuvant Therapy
Endocrine Practice, 2013, 19, 149-156
3.310Citations (PDF)
144Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies
Endocrine, 2013, 47, 266-272
2.527Citations (PDF)
145Oncologic Outcomes After Completion Thyroidectomy for Patients with Well-Differentiated Thyroid Carcinoma
Annals of Surgical Oncology, 2013, 21, 1374-1378
2.341Citations (PDF)
146Recombinant Human Thyroid Stimulating Hormone–Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence
Thyroid, 2012, 22, 1007-1015
4.476Citations (PDF)
147Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic BRAF , the Number of Nodal Metastases, and Extra-Nodal Extension
Thyroid, 2012, 22, 575-584
4.4116Citations (PDF)
148Even Without Additional Therapy, Serum Thyroglobulin Concentrations Often Decline for Years After Total Thyroidectomy and Radioactive Remnant Ablation in Patients with Differentiated Thyroid Cancer
Thyroid, 2012, 22, 778-783
4.487Citations (PDF)
149The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma Can Be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension
Thyroid, 2012, 22, 1144-1152
4.4749Citations (PDF)
150American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Thyroid, 2012, 22, 1104-1139
4.4776Citations (PDF)
151Changing trends in well differentiated thyroid carcinoma over eight decades5.437Citations (PDF)
152American Thyroid Association Statement on the Essential Elements of Interdisciplinary Communication of Perioperative Information for Patients Undergoing Thyroid Cancer Surgery
Thyroid, 2012, 22, 395-399
4.471Citations (PDF)
153Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell–Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy 131 I Whole-Body Scans
Thyroid, 2012, 22, 877-883
4.459Citations (PDF)
154American Thyroid Association Design and Feasibility of a Prospective Randomized Controlled Trial of Prophylactic Central Lymph Node Dissection for Papillary Thyroid Carcinoma
Thyroid, 2012, 22, 237-244
4.4209Citations (PDF)
155Iatrogenic hyperthyroidism does not promote weight loss or prevent ageing‐related increases in body mass in thyroid cancer survivors
Clinical Endocrinology, 2012, 76, 582-585
2.330Citations (PDF)
156Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy
Clinical Endocrinology, 2012, 77, 132-138
2.3247Citations (PDF)
157Ultrasonographically Detected Small Thyroid Bed Nodules Identified After Total Thyroidectomy for Differentiated Thyroid Cancer Seldom Show Clinically Significant Structural Progression
Thyroid, 2011, 21, 845-853
4.4130Citations (PDF)
158Similarities and Differences in Follicular Cell-Derived Thyroid Cancer Management Guidelines Used in Europe and the United States4.911Citations (PDF)
159A Risk-Adapted Approach to the Use of Radioactive Iodine and External Beam Radiation in the Treatment of Well-Differentiated Thyroid Cancer
Cancer Control, 2011, 18, 89-95
2.237Citations (PDF)
160Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer
Clinical Endocrinology, 2011, 75, 112-119
2.3180Citations (PDF)
161Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy
Cancer, 2011, 117, 4439-4446
4.0287Citations (PDF)
162Disease-Related Death in Patients Who Were Considered Free of Macroscopic Disease After Initial Treatment of Well-Differentiated Thyroid Carcinoma
Thyroid, 2011, 21, 501-504
4.423Citations (PDF)
163In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin Response
Thyroid, 2011, 21, 1317-1322
4.4130Citations (PDF)
164Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer0.57Citations (PDF)
165Radioactive Iodine Administered for Thyroid Remnant Ablation Following Recombinant Human Thyroid Stimulating Hormone Preparation Also Has an Important Adjuvant Therapy Function
Thyroid, 2010, 20, 257-263
4.461Citations (PDF)
166Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System
Thyroid, 2010, 20, 1341-1349
4.4863Citations (PDF)
167The Effect of Posttherapy 131I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer
Journal of Nuclear Medicine, 2010, 51, 1361-1367
5.5110Citations (PDF)
168Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study
Human Pathology, 2010, 41, 172-180
2.380Citations (PDF)
169Mild Decreases in White Blood Cell and Platelet Counts Are Present One Year After Radioactive Iodine Remnant Ablation
Thyroid, 2009, 19, 1035-1041
4.445Citations (PDF)
170Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Thyroid, 2009, 19, 1167-1214
4.46,330Citations (PDF)
171Encapsulated Papillary Thyroid Carcinoma: A Clinico-Pathologic Study of 106 Cases with Emphasis on Its Morphologic Subtypes (Histologic Growth Pattern)
Thyroid, 2009, 19, 119-127
4.4134Citations (PDF)
172Medical management of thyroid cancer: a risk adapted approach
Journal of Surgical Oncology, 2008, 97, 712-716
1.558Citations (PDF)
173Follow up Approaches in Thyroid Cancer: A Risk Adapted Paradigm3.5107Citations (PDF)
174ret/PTC Activation Is Not Associated with Individual Radiation Dose Estimates in a Pilot Study of Neoplastic Thyroid Nodules Arising in Russian Children and Adults Exposed to Chernobyl Fallout
Thyroid, 2008, 18, 839-846
4.424Citations (PDF)
175Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal
Journal of Nuclear Medicine, 2008, 49, 764-770
5.5146Citations (PDF)
176Risk-Adapted Management of Thyroid Cancer
Endocrine Practice, 2008, 14, 764-774
3.383Citations (PDF)
177Impact of Pregnancy on Serum Thyroglobulin and Detection of Recurrent Disease Shortly After Delivery in Thyroid Cancer Survivors
Thyroid, 2007, 17, 543-547
4.456Citations (PDF)
178Papillary Thyroid Cancer: Monitoring and Therapy3.574Citations (PDF)
179Microarray Comparative Genomic Hybridization Reveals Genome-Wide Patterns of DNA Gains and Losses in Post-Chernobyl Thyroid Cancer
Radiation Research, 2006, 166, 519-531
2.124Citations (PDF)
180Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
Thyroid, 2006, 16, 109-142
4.41,898Citations (PDF)
181Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis
Cancer, 2006, 106, 1286-1295
4.0305Citations (PDF)
182Follicular variant of papillary thyroid carcinoma
Cancer, 2006, 107, 1255-1264
4.0382Citations (PDF)
183Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning4.1550Citations (PDF)
184BRAF Mutations are Uncommon in Papillary Thyroid Cancer of Young Patients
Thyroid, 2005, 15, 320-325
4.4114Citations (PDF)
185Thyroid Cancers Express CD-40 and CD-40 Ligand: Cancers That Express CD-40 Ligand May Have a Greater Risk of Recurrence in Young Patients
Thyroid, 2005, 15, 105-113
4.49Citations (PDF)
186Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes2.155Citations (PDF)
187Ret/PTC Activation in Benign and Malignant Thyroid Tumors Arising in a Population Exposed to Low-Dose External-Beam Irradiation in Childhood4.144Citations (PDF)
188Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma4.175Citations (PDF)
189Differentiated Thyroid Carcinomas from Children and Adolescents Express IGF-I and the IGF-I Receptor (IGF-I-R). Cancers with the Most Intense IGF-I-R Expression May Be More Aggressive
Pediatric Research, 2004, 55, 709-715
2.333Citations (PDF)
190Cytoplasmic Localization of the Paired Box Gene, Pax-8, is Found in Pediatric Thyroid Cancer and May Be Associated With a Greater Risk of Recurrence
Thyroid, 2004, 14, 1037-1046
4.420Citations (PDF)
191Papillary Thyroid Carcinomas from Young Adults and Children Contain a Mixture of Lymphocytes4.167Citations (PDF)
192Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults2.16Citations (PDF)
193Vascular Endothelial Growth Factor Monoclonal Antibody Inhibits Growth of Anaplastic Thyroid Cancer Xenografts in Nude Mice
Thyroid, 2002, 12, 953-961
4.465Citations (PDF)
194Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents
Pediatric Research, 2002, 52, 737-744
2.357Citations (PDF)
195Is the Serum Thyroglobulin Response to Recombinant Human Thyrotropin Sufficient, by Itself, to Monitor for Residual Thyroid Carcinoma?4.1136Citations (PDF)
196Intense Expression of the B7-2 Antigen Presentation Coactivator Is an Unfavorable Prognostic Indicator for Differentiated Thyroid Carcinoma of Children and Adolescents4.120Citations (PDF)
197Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents
Pediatric Research, 2002, 52, 737-744
2.37Citations (PDF)
198Expression of the Sodium Iodide Symporter and Thyroglobulin Genes Are Reduced in Papillary Thyroid Cancer
Modern Pathology, 2001, 14, 289-296
4.895Citations (PDF)
199Infiltration of Differentiated Thyroid Carcinoma by Proliferating Lymphocytes Is Associated with Improved Disease-Free Survival for Children and Young Adults14.178Citations (PDF)
200Resistance of [18F]-Fluorodeoxyglucose-Avid Metastatic Thyroid Cancer Lesions to Treatment with High-Dose Radioactive Iodine
Thyroid, 2001, 11, 1169-1175
4.4178Citations (PDF)
201The Chernobyl accident and its consequences: Update at the millennium
Seminars in Nuclear Medicine, 2000, 30, 133-140
4.9137Citations (PDF)
202Theret/PTC Mutations Are Common in Sporadic Papillary Thyroid Carcinoma of Children and Young Adults14.1203Citations (PDF)
203Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma
Thyroid, 0, ,
4.47Citations (PDF)
204RAS -Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance
Thyroid, 0, ,
4.46Citations (PDF)
205Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients4.11Citations (PDF)
206The prognostic impact of blood vessel invasion in infiltrative papillary thyroid carcinoma: a retrospective case–control study
Histopathology, 0, 88, 673-682
3.60Citations (PDF)
207Scholarly Dialogue on Risk to the Recurrent Laryngeal Nerve with Thermal Ablation Procedures: A Reflection on Empirical Practices
Thyroid, 0, 35, 1221-1229
4.40Citations (PDF)
208Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance0.30Citations (PDF)
209Clinical and genomic characterization of brain metastasis in thyroid cancer2.50Citations (PDF)
210Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma3.00Citations (PDF)